Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer – Results from a prospective cohort study
Authors Marschner N, Arnold D, Engel E, Hutzschenreuter U, Rauh J, Freier W, Hartmann H, Frank M, Jänicke M
Received 6 September 2014
Accepted for publication 6 December 2014
Published 20 April 2015 Volume 2015:7 Pages 295—303
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Professor Henrik Toft Sørensen
Norbert Marschner,1 Dirk Arnold,2 Erik Engel,3 Ulrich Hutzschenreuter,4 Jacqueline Rauh,5 Werner Freier,6 Holger Hartmann,7 Melanie Frank,8 Martina Jänicke7
On behalf of the TKK Registry Group
1Praxis für Interdisziplinäre Onkologie und Hämatologie, 2Klinik für Tumorbiologie, Freiburg, Germany; 3Hämatologisch – Onkologische Praxis Altona, Hamburg, Germany; 4Hämatologisch – Onkologische Gemeinschaftspraxis, Nordhorn, Germany; 5Fachinternistische Gemeinschaftspraxis und Therapiezentrum, Witten, Germany; 6Onkologische Praxis, Hildesheim, Germany; 7Clinical Epidemiology and Health Economics, iOMEDICO, 8Statistics, iOMEDICO, Freiburg, Germany
Purpose: Several randomized trials investigating the preferable first-line combination chemotherapy regimen for metastatic colorectal cancer have shown inconsistent findings. Because a substantial number of patients are still being treated with "chemo-only" first-line therapies without targeted agents, we compared overall survival (OS) of patients treated in routine practice with oxaliplatin–fluoropyrimidine and irinotecan–fluoropyrimidine.
Patients and methods: Using the database of the Tumor Registry Colorectal Cancer, we identified 605 patients with metastatic colorectal cancer who received first-line fluoropyrimidine combination chemotherapy with either oxaliplatin (n=430) or irinotecan (n=175). The Tumor Registry Colorectal Cancer is a cohort study that prospectively documents treatment of colorectal cancer by office-based medical oncologists in Germany and has recruited over 5,000 patients. OS was estimated using the Kaplan–Meier method, and a multivariate Cox proportional hazard model was used to adjust for potentially confounding variables.
Results: Median OS was 26.8 (95% confidence interval [CI] 22.4–31.9) months with an oxaliplatin–fluoropyrimidine combination and 18.3 (95% CI 15.1–23.2) months with irinotecan–fluoropyrimidine first-line "chemo-only" therapy. Median progression-free survival was 9.0 (8.1–10.2) and 7.9 (7.2–10.2) months, respectively. The difference in OS was confirmed if analysis was restricted to patients with synchronous metastases (no prior treatment). Among other variables, proportion of patients receiving any second-line therapy did not differ between groups. Oxaliplatin-based first-line therapy was associated with improved OS in multivariate analysis adjusted for potentially confounding variables (hazard ratio 0.678, 95% CI 0.510–0.901, P=0.007).
Conclusion: In clinical routine practice, first-line treatment with oxaliplatin–fluoropyrimidine combination chemotherapy compared to irinotecan–fluoropyrimidine combination is associated with improved survival in patients with metastatic colorectal cancer, independent of all examined potentially confounding factors.
Keywords: colorectal neoplasms, epidemiology, irinotecan, oxaliplatin, cohort studies, treatment outcome
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]